Illumina Inc

Illumina trades at a 24.2x P/E despite sitting 7.7% short of float—suggesting modest skepticism from bears. The stock sits comfortably at RSI 59.5, neither overbought nor oversold, indicating equilibrium between buyers and sellers. At $18.4B market cap, the valuation premium reflects biotech sequencing dominance, yet the absence of any squeeze signal and mid-range momentum suggest the market has already priced in growth expectations. The stock isn't at 52-week highs, hinting earlier enthusiasm has cooled, making the elevated multiple a potential headwind if execution stumbles or growth guidance disappoints.